Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Lung Neoplasms 12Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Breast Neoplasms 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Lymphoid Interstitial Pneumonia 2Liposarcoma 2

Interventions

Nivolumab 3Cisplatin 3atezolizumab 2Irinotecan 2Ipilimumab 2Etoposide 2Carboplatin 2tivozanib 1repotrectinib 1niraparib 1gallium Ga 68 dotatate 1dostarlimab 1cabozantinib 1budigalimab 1belinostat 1Topotecan 1Temozolomide 1Specimen Handling 1Radiosurgery 1Radionuclide Imaging 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Magnetic Resonance Spectroscopy 1Leucovorin 1Immunoglobulin G 1IFL protocol 1Fluorouracil 1Disulfides 1DLL3 protein, human 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × Immunoglobulin G × 90 days × Clear all
NCT04701307 2026-04-22

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
48 enrolled
EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡